20 billion solution agent market, these domestic brands soared 30%!

"
Pharmaceutical Network Market Analysis" In recent years, with the aging and the superposition effect of the second child age, the market demand for oral liquid agent is growingData show that in 2019, the market size of China's public medical institutions terminal chemical solution agent will be the first to break 20 billion, with a growth rate of 12.35 percent, higher than the 5.77 percent growth rate of the overall size of chemical drugsAmong them, the threshold of the first 20 brands of internal service solution agent has risen to 235 million yuanIt is worth noting that from the sales growth rate, there are three domestic brands sales growth rate has exceeded 30%20 billion solution agent market, these domestic brands surged 30%Zhejiang Iwu Biologicaldust dropletgrowth growth rate: 36.92%dust tick drip is the core product of my wu biological, mainly used for allergic rhinitis caused by dust tick allergy, allergic asthma desensitization treatmentAs a few domestic production of standardized under-the-tongue desensitization drugs companies, in the field of desensitization treatment, I wu biological has been occupying a leading positionSince 2012, its production of "dust tick slyd drops" in the domestic dust mites-type desensitization drug market continued to maintain the forefront of the market, competitiveness is very strongWith the intensification of air pollution in recent years, the incidence of allergic rhinitis, allergic asthma continues to increase, the market demand for dust drops is increasing year by year, in 2019 I Wu biological dust ticks in China's public medical institutions terminal sales have exceeded 600 million yuan, accounting for 98.65 percent of the company's total revenueAccording to its annual report released in April, dust droplets are currently undergoing Phase III clinical trials for the treatment of aispecialed dermatitis caused by dust aphid allergy, and if successful, the market size of its desensitization treatment is expected to be further expandedZhejiang Kant Pharmaceuticalsthe growth rate of ammonia hemp-methedry suspension agent: 33.92% aminopol methane dry suspension agent is the main product of Zhejiang Kant Pharmaceutical Group, is tailored for children's cold medicine, suitable for the relief of children's common cold and influenza caused by fever, headache, limb pain, sneezing, nose, nose, cough, sore throat and other symptoms Sales of the product exceeded the 200 million yuan mark in 2019, with a growth rate of 33.92% In the future, with the expansion of the children's drug market, its share of sales may rise further 　State Drug Holdings Star Shark Pharmaceutical (Xiamen) vitamin D drops growth rate: 31.61% Vitamin D drops is a vitamin preparation spent to prevent and treat vitamin D deficiency, mainly in the hospital market According to the China Vitamin D Drops Market Assessment and Investment Strategy Report (2019 edition), china's market demand for vitamin preparations has grown rapidly in recent years, with sales of vitamin preparations in China increasing from 16.121 billion yuan to 22.648 billion yuan in 2013-2017, with a compound growth rate of 8.87 percent in the last five years With this trend, its market will be very impressive in the future The vitamin D drops of China National Drug Holdingstar Pharmaceuticals (Xiamen) is its main product, mainly used to prevent vitamin D deficiency of rickets, as well as the prevention of osteoporosis In 2019, sales of the product have also exceeded the 200 million yuan mark, a growth rate of 31.61 percent Under the trend of expanding vitamin D drops in China, the market prospects of this product are generally optimistic in the industry.